Regentis Biomaterials Ltd. (NYSE American: RGNT) is making strides in both the U.S. clinical and European commercial arenas for its GelrinC cartilage repair platform, a move that could compress the typically lengthy timeline between regulatory approval and market availability for medical devices.
The company announced that it has surpassed 50% enrollment in the pivotal Phase III SAGE study of GelrinC, with recruitment completion targeted for the third quarter of 2026. Following that, the company expects to begin the Pre-Market Approval (PMA) process with the U.S. Food and Drug Administration (FDA) by the end of 2027. The FDA has approved a single-arm protocol that uses a historical microfracture control data package owned by Regentis. According to the company, the first 40 patients in the study closely match this control group, which may strengthen the validity of the trial results.
In Europe, where GelrinC already holds CE Mark approval, Regentis is focusing on commercial expansion. Surgeon training began in the third quarter of 2026 at Humanitas Research Hospital in Milan, supported by an expanded clinical site network and a newly approved manufacturing process that increases yield by approximately 400%. This manufacturing scale-up is crucial to meet the demands of a broader commercial launch.
The parallel advancement of clinical and commercial activities is a strategic move for Regentis. For development-stage medical technology companies, regulatory approval and commercial revenue often sit years apart. A trial needs to be finished, a submission must clear review, manufacturing has to scale, surgeons must be trained, and distribution has to be built. Companies able to run these workstreams in parallel rather than in sequence can significantly reduce the time to market.
GelrinC is a cell-free, off-the-shelf hydrogel implant designed to treat focal articular cartilage defects in the knee. Unlike traditional approaches that require harvesting a patient’s cells, expanding them in a lab, and performing a second surgery to implant them, GelrinC is ready to use and can be implanted in a procedure lasting roughly 10 minutes. The hydrogel forms a temporary programmed matrix inside the defect, facilitating cartilage repair.
The company’s progress is notable for the orthopedic community and investors alike. By moving GelrinC along parallel tracks, Regentis aims to bring this innovative therapy to patients faster, potentially improving outcomes for those suffering from knee cartilage damage. The successful execution of this strategy could position Regentis as a key player in the cartilage repair market, which is expected to grow as the population ages and seeks minimally invasive treatments.
For more information on Regentis Biomaterials and GelrinC, including recent updates, visit the company’s newsroom at ibn.fm/RGNT. Investors and interested parties can also review the full terms of use and disclaimers on the BioMedWire website at https://www.BioMedWire.com/Disclaimer.
